Feng Ma

Dr. Feng Ma

Suzhou Institute of Systems Medicine, Chinese Academy of Medical Sciences & Peking Union Medical College, Suzhou 215123, China
orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2021 in Cancer Letters
Verified
Journal Article
Closed access
YYYi Yuan
Yi Yuan
XCXushan Cai
Xushan Cai
FSFangrong Shen
Fangrong Shen
Feng MaFeng Ma
Feng Ma

1 October 2019 in Cell Reports
Verified
Journal Article
Open access
DLDapei Li
Dapei Li
RWRongsheng Wu
Rongsheng Wu
WGWen Guo
Wen Guo
LXLifen Xie
Lifen Xie
ZQZigang Qiao
Zigang Qiao
Feng MaFeng Ma
Feng Ma
γ-interferon-inducible protein-16 (IFI16), a key DNA sensor, triggers downstream STING-dependent type I interferon (IFN-I) production and antiviral immunity. However, it is still unclear how to negatively regulate IFI16 to avoid excessive IFN-I production and autoimmunity. Here, we find that STING directly interacts with IFI16 and facilitates IFI16 degradation via the ubiquitin-proteasome pathway by recruiting the E3 ligase TRIM21. The 1-pyrin region of IFI16 is responsible for the IFI16-STING interaction, and the first three lysines in the N-terminal region of IFI16 are the key sites that lead to STING-mediated IFI16 ubiquitination and degradation. Compared to wild-type IFI16, a higher level of viral DNA triggered IFN-β and antiviral IFN-stimulated gene expression, and thus less HSV-1 infection, was observed in the cells transfected with IFI16-K3/4/6R, an IFI16 mutant that is resistant to degradation. STING-mediated negative feedback regulation of IFI16 restricts IFN-I overproduction during antiviral immunity to avoid autoimmune diseases.

29 January 2021 in Immunology
Verified
Journal Article
Closed access
PDF file
SCShengchuan Chen
Shengchuan Chen
JZJingfei Zhu
Jingfei Zhu
LSLi‐Qiong Sun
Li‐Qiong Sun
SLSiying Liu
Siying Liu
TZTan Zhang
Tan Zhang
Feng MaFeng Ma
Feng Ma

9 September 2024 in Cellular & Molecular Immunology
Verified
Journal Article
Closed access
PDF file
YZYunkai Zhang
Yunkai Zhang
YGYing Gao
Ying Gao
YWYujia Wang
Yujia Wang
YJYuyu Jiang
Yuyu Jiang
YXYan Xiang
Yan Xiang
XLXingguang Liu
Xingguang Liu

6 March 2023 in EMBO Reports
Verified
Journal Article
Closed access
YZYibo Zuo
Yibo Zuo
ZZZhijin Zheng
Zhijin Zheng
YHYingkang Huang
Yingkang Huang
JHJiuyi He
Jiuyi He
LZLichao Zang
Lichao Zang
HZHui Zheng
Hui Zheng

8 April 2022 in Science Advances
Verified
Journal Article
Open access
YZYibo Zuo
Yibo Zuo
JHJiuyi He
Jiuyi He
SLSiying Liu
Siying Liu
YXYing Xu
Ying Xu
JLJin Liu
Jin Liu
HZHui Zheng
Hui Zheng
Interferons (IFNs) have broad-spectrum antiviral activity to resist virus epidemic. However, IFN antiviral efficacy needs to be greatly improved. Here, we reveal that LATS1 is a vital signal transmitter governing full type-I IFN (IFN-I) signaling activity. LATS1 constitutively binds with the IFN-I receptor IFNAR2 and is rapidly tyro-phosphorylated by Tyk2 upon IFN-I engagement. Tyro-phosphorylation of LATS1 promotes LATS1 activation and YAP degradation, thereby promoting IFN-mediated antiproliferation activity. Moreover, activated LATS1 translocates into the nucleus and induces CDK8-Ser62 phosphorylation, which in turn phosphorylates STAT1 at Ser 727 and induces full IFN-I antiviral activity. LATS1 deficiency restricts in vivo IFN-I signaling and attenuates host antiviral immune response. Our study identifies IFN-I as a previously unidentified extracellular diffusible ligand signal for activation of the Hippo core LATS1 pathway and reveals Tyk2-LATS1-CDK8 as a complete signaling cascade controlling full IFN-I activity.